Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study.

For each of the 3 trials of an anabolic followed by an antiresorptive, we checked whether the trial’s difference in the percent change in THBMD between the investigated drug and control at 24 mo exceeded the STEs and, if so, whether the trial reported a nominally significant reduction in fracture risk ( p < .05).

also in 7,732 other papers